CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 75 enrolled
Drug / intervention
Eyhance IOL +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05069415
NCT05069415N/ACompleted
CompareCT.gov

Visual Performance and Patient Satisfaction With A New Monofocal Intraocular Lens

Carolina Eyecare Physicians, LLC·interventional·Posted Oct 6, 2021·Updated Feb 13, 2024

In Brief

A clinical study evaluating Eyhance IOL for Cataract and Presbyopia. Completed, enrolled 75 participants across 2 sites.

Detailed Summary

This study is a 3-month, prospective, up to 2 center, bilateral, randomized subject masked clinical evaluation of a monofocal intraocular lens (IOL) when both eyes are targeted for emmetropia and when the non-dominant eye is targeted for mini monovision (-0.75 D) in patients with or without astigmatism undergoing routine cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract, Presbyopia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 6, 2021
Enrollment StartOct 4, 2021
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.7 years ago

Interventions

Eyhance IOLdevice

Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.

Eyhance IOLdevice

Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.